ALNY Alnylam Pharmaceuticals


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
AgricultureAirClimate ChangeEcosystemEmissionEnergy EfficiencyEnvironmentEnvironmentalGHGGHG EmissionsGreenhouse GasMaterialsNatureNuclearOffsetPackagePandemicPlanetRaw MaterialsToxicWasteWaterAccessAffinity GroupAffordabilityAttritionBenefitsBlackCalifornia Consumer Privacy ActCollective BargainingCommunityCultureCustomerCyberCybersecurityData PrivacyDeathDemographicsDisabilityDiversityDiversity and InclusionDrug PricingEmployeeEmployee EngagementEmployee RetentionEngagementEthnicEthnicityGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesIncidentIndigenousInjuredInjuriesInjuryLatinxLGBTQMinorityOvertimePerquisitesPrivacyProduct SafetyRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkersWorkforceWorkplace SafetyAction PlanAnti-corruptionAntitrustAssessmentAssuranceAuditBonusBribeBriberyChronicClass Action LawsuitClassifiedClassified BoardClawbackCommitmentConflict of InterestCorporate GovernanceDepartment ofDirector ResignationEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIncentivizeIndependenceIndependentInnovationInnovativeInvestigationLawsuitLeadershipLitigantLitigationLong-termMajorityMissionOverseeOversightPerquisitePlaintiffPledgingProcurementPurposeQuality StandardR&DReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationStewardshipStockholder EngagementStrategySustainabilitySustainableTargetsTaxTenureTransparencyVoting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Alnylam Pharmaceuticals, Inc. (the “Company”) was held on May 18, 2021. As of March 29, 2021, the record date for the Annual Meeting, 117,320,127 shares of the Company’s common stock were issued and outstanding. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

1. The Company’s stockholders re-elected the four persons listed below as Class II directors, each to serve until the Company’s 2024 annual meeting of stockholders or until his or her successor is duly elected and qualified. The voting results were as follows:

Votes ForVotes
AbstentionsBroker Non-Votes
Dennis A. Ausiello, M.D.100,520,0541,188,2726,4973,978,315
Olivier Brandicourt, M.D.99,910,4831,793,71310,6273,978,315
Marsha H. Fanucci95,079,0326,627,4618,3303,978,315
David E.I. Pyott95,819,5925,887,3417,8903,978,315

The terms of office of the following directors continued after the Annual Meeting:

Michael W. Bonney

Margaret A. Hamburg, M.D.

John M. Maraganore, Ph.D.

Steven M. Paul, M.D.

Colleen F. Reitan

Amy W. Schulman

Phillip A. Sharp, Ph.D.

2. The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers. The voting results were as follows:

Votes ForVotes AgainstAbstentionsBroker Non-Votes

3. The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2021. The voting results were as follows:

Votes ForVotes AgainstAbstentionsBroker Non-Votes